DR. PENG(SH:600804)2024-04-26 11:51Financial Performance - The company expects a net loss of approximately -93.25 million yuan for the fiscal year 2023, a significant revision from the previously estimated profit of 31.25 million yuan[1][4] - The adjusted net profit attributable to shareholders, excluding non-recurring gains and losses, is projected to be -129.19 million yuan for 2023[1][4] - The previous year's net profit was -453.25 million yuan, indicating a worsening financial performance year-over-year[1][5] Impairment and Provisions - The company anticipates recognizing fixed asset and goodwill impairment losses of 55.68 million yuan, which is an increase of 25.46 million yuan from earlier estimates[1][6] - The company plans to increase provisions for litigation and arbitration liabilities, resulting in an additional expense of approximately 37.74 million yuan[1][6] - Deferred income tax expenses have been adjusted, leading to a reduction in net profit by about 37.71 million yuan[1][6] Investment Income - Investment income from joint ventures is expected to decrease by 8.42 million yuan due to adjustments based on audit reports[1][6] Going Concern and Audit Opinion - The company faces significant uncertainty regarding its ability to continue as a going concern, which may lead to a disclaimer of opinion from auditors[2][7] - If the annual report receives a disclaimer of opinion, the company's stock may be subject to delisting risk warnings according to stock exchange regulations[2][7] - The company has communicated with its auditors regarding the adjustments and confirmed that there are no significant disagreements on the revised financial data[1][8]